Keros Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
During the three months ended March 31, 2026, the following director of the Company adopted a “Rule 10b5-1 trading arrangement,” as that term is defined in Item 408(a) of Regulation S-K, which was entered into during an open trading window in accordance with the Company’s Insider Trading Policy and which was intended to satisfy Rule 10b5-1(c):
On March 12, 2026, Charles Newton, amember of our board of directors, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 2,201 shares of our common stock to be acquired upon the settlement of RSUs. The plan will expire on February 28, 2027, subject to early termination for certain specified events set forth in the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.